Abstract
Monoclonal anti-IgE antibody omalizumab is a promising therapeutic option in patients with chronic urticaria resistant to non-sedating H1-antihistamines. However, data about its long-term efficacy and safety are still scant, especially from the Middle East. We describe the long-term clinical course of patients with severe recalcitrant chronic urticaria that was treated with omalizumab in our allergy center in Kuwait, for periods up to 4 years.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
